Kite Shows Yescarta Data for Outpatient Lymphoma Care at ASCO
01 Jun 2025 //
BUSINESSWIRE
Gilead bolsters Trodelvy with first-line breast cancer win
30 May 2025 //
FIERCE PHARMA
ASCENT-03 Trodelvy Shows Benefit in 1L mTNBC Patients
23 May 2025 //
BUSINESSWIRE
Gilead`s Trodelvy Chalks up Another Phase 3 Breast Cancer Win
23 May 2025 //
FIERCE PHARMA
Gilead pays partner Hookipa $10M for HBV, HIV vaccines
23 May 2025 //
FIERCE BIOTECH
Tomas Cihlar of Gilead Sciences on TIME`s 100
20 May 2025 //
ACCESSWIRE
Gilead Sciences Ireland signs MoU for public health in Abu Dhabi
16 May 2025 //
BIOSPECTRUM
Gilead and Kite to Present Data at 2025 ASCO and EHA
15 May 2025 //
BUSINESSWIRE
Gilead Sciences: Focusing on PBC Through Patient Stories
15 May 2025 //
ACCESSWIRE
Gilead tees up $11B in new US manufacturing, R&D investments
09 May 2025 //
FIERCE PHARMA
Earth Day Focus for Gilead Sciences - Every Action Has an Impact
08 May 2025 //
ACCESSWIRE
Gilead’s Livdelzi Shows Consistent Efficacy in PBC at EASL
07 May 2025 //
BUSINESSWIRE
Bulevirtide Study Shows Sustained Viral Suppression
07 May 2025 //
BUSINESSWIRE
The Centrifuge Sessions Focus on Fighting Devastating Diseases
06 May 2025 //
ACCESSWIRE
Gilead to pay $202 M in US settlement over HIV drug kickbacks
30 Apr 2025 //
REUTERS
Gilead to Present Latest Advancements in Liver Diseases
29 Apr 2025 //
BUSINESSWIRE
Gilead Sciences to Present at Upcoming Investor Conferences
29 Apr 2025 //
BUSINESSWIRE
Gilead supports long-acting PrEP launch despite uncertainties
25 Apr 2025 //
FIERCE PHARMA
Gilead posts profit, HIV prevention drug on track for mid-June
24 Apr 2025 //
REUTERS
Gilead Sciences Announces First Quarter 2025 Financial Results
24 Apr 2025 //
BUSINESSWIRE
Gilead mounts campaign to close UK’s ‘HIV gender gap’
23 Apr 2025 //
FIERCE PHARMA
Gilead Backs HIV Prevention Summit in Atlanta
22 Apr 2025 //
ACCESSWIRE
Gilead says Trodelvy-Keytruda combo effective for breast cancer
22 Apr 2025 //
REUTERS
Ipsen touts early launch results for liver disease drug Iqirvo
17 Apr 2025 //
FIERCE PHARMA
Nurix`s GS-6791/NX-0479 IRAK4 Degrader IND Cleared by FDA
17 Apr 2025 //
GLOBENEWSWIRE
Gilead Reprimanded Over Conference Wi-Fi Sponsorship
14 Apr 2025 //
FIERCE PHARMA
IDEAYA Biosciences Expands IDE397 and Trodelvy Combo in MTAP-Dele
10 Apr 2025 //
PR NEWSWIRE
Gilead Sciences to Release Q1 2025 Financial Results on April 24
10 Apr 2025 //
BUSINESSWIRE
Centrifuge Sessions Drive Cancer Research Innovation
03 Apr 2025 //
ACCESSWIRE
Gilead Sciences in Top Five on JUST List for Biopharma Companies
18 Mar 2025 //
ACCESSWIRE
Gilead Sciences - Women`s History Month Celebrated With Its Team
14 Mar 2025 //
ACCESSWIRE
Gilead Reveals New HIV Treatment and Cure Data at CROI 2025
12 Mar 2025 //
BUSINESSWIRE
Gilead sets aside $200M for settlement over HIV drug
05 Mar 2025 //
FIERCE PHARMA
MEDSIR, Debiopharm Dose First Patient In WIN-B Breast Cancer Trial
25 Feb 2025 //
BUSINESSWIRE
EMA Validates Gilead’s MAA For Lenacapavir In HIV Prevention
24 Feb 2025 //
BUSINESSWIRE
Gilead`s Seladelpar Gets EU Conditional Nod For Biliary Cholangitis
20 Feb 2025 //
BUSINESSWIRE
Gilead Showcases Autoimmune Impact In The Centrifuge Sessions
19 Feb 2025 //
ACCESSWIRE
Gilead Sciences to Present at Upcoming Investor Conferences
19 Feb 2025 //
BUSINESSWIRE
FDA Grants Review To Gilead’s Lenacapavir For HIV Prevention
18 Feb 2025 //
BUSINESSWIRE
Nurix Reports Inducement Grants Under Nasdaq LR 5635(c)(4)
14 Feb 2025 //
GLOBENEWSWIRE
Ideaya & Gilead To Study Trodelvy + IDE397 Combo In MTAP-Deleted NSCLC
13 Feb 2025 //
PR NEWSWIRE
Gilead provides upbeat 2025 forecast, shares rise 4%
12 Feb 2025 //
REUTERS
GSK questions Gilead`s potential dominance of the PrEP market
07 Feb 2025 //
FIERCE PHARMA
Energize Supports Global Healthcare Firms with Multi-buyer PPA
06 Feb 2025 //
BUSINESSWIRE
Gilead to Release Q4 & Full Year 2024 Financial Results Feb 11
28 Jan 2025 //
BUSINESSWIRE
Gilead, US government resolve long-running HIV patent dispute
17 Jan 2025 //
PRESS RELEASE
Gilead, LEO Pharma to programs for inflammatory diseases
13 Jan 2025 //
REUTERS
Galapagos splits in 2, laying off 40% of staff
08 Jan 2025 //
FIERCE BIOTECH
Gilead Sciences to Present at Upcoming Investor Conference
20 Dec 2024 //
BUSINESSWIRE
Merck`s HIV combo treatment meets efficacy bar in Ph 3 trials
20 Dec 2024 //
FIERCE BIOTECH
Gilead & Terray Announce Multi-Target Research Collaboration
17 Dec 2024 //
BUSINESSWIRE
AI-powered Terray is teaming up with Gilead in a fresh R&D pact
17 Dec 2024 //
FIERCE BIOTECH
Gilead`s Seladelpar Receives CHMP Nod For Biliary Cholangitis
13 Dec 2024 //
BUSINESSWIRE
Gilead appoints Sanofi official Dietmar as next CMO
13 Dec 2024 //
REUTERS
ICER calls out drugmakers over `unsupported` price hikes
12 Dec 2024 //
REUTERS
Gilead spotlights lenacapivir in plan to hold on to HIV crown
11 Dec 2024 //
FIERCE PHARMA
Kite’s Tecartus CAR T Therapy Shows Durable Efficacy at ASH 2024
09 Dec 2024 //
BUSINESSWIRE
Kite`s Yescarta® Shows Durable Response in Relapsed Lymphomas
09 Dec 2024 //
BUSINESSWIRE
Kite`s Yescarta® Highlights Curative Potential in Relapsed Lymphoma
08 Dec 2024 //
BUSINESSWIRE
Gilead taps Tubulis for solid tumor ADC development worth up to $465M
04 Dec 2024 //
PRESS RELEASE